Stock PRDS PARDES BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Pardes Biosciences, Inc.

Equities

PRDS

US69945Q1058

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pardes Biosciences Goes Public Following Merger With Blank Check Firm FS Development
MT
FS II : Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19 - Form 8-K
PU
Pardes Biosciences, Inc. completed the acquisition of FS Development Corp. II from FS Development Holdings II, LLC, Daniel Dubin, Owen Hughes, Deepa Pakianathan, and others in a reverse merger transaction.
CI
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections
BU
FS II : FSII and Pardes Biosciences Move Towards Merger with the Goal of Tackling COVID-19 Via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections - Form 8-K
PU
FS Development Corp. II Registration Statement for Merger with Pardes Declared Effective by SEC
MT
FS DEVELOPMENT CORP. II : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)
AQ
FS Development Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
FS Development II : Pardes Biosciences Starts Phase 1 Study On Potential COVID-19 Treatment Ahead Of Merger With FS Development
MT
Fs Development Corp. Ii Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
FS Development II : Blank-Check Firm FS Development II to Merge With Pardes Biosciences
MT
FS Development II : Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections (Form 8-K)
PU
FS Development II : Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections
BU
Pardes Biosciences, Inc. entered into a definitive merger agreement to acquire FS Development Corp. II from FS Development Holdings II, LLC, Daniel Dubin, Owen Hughes, Deepa Pakianathan, and others for approximately $320 million in a reverse merger transaction.
CI
Fs Development Corp. Ii Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
FS Development Corp. II Announces Appointment of Directors
CI
FS Development Corp. II has completed an IPO in the amount of $175 million.
CI
FS Development Corp. II has filed an IPO in the amount of $100 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRDS Stock
  4. News Pardes Biosciences, Inc.
  5. Highlights